ECE2022 Poster Presentations Reproductive and Developmental Endocrinology (61 abstracts)
The medical treatment of polycystic ovary syndrome: effects of inositol isomers and metformin on clinical, metabolic and hormonal profile
Nunzia Verde 1 , Bianca Pellegrini 1 , Lucia Auriemma 1 , Alessia Baratto 1 , Cristina De Angelis 1 , Francesco Garifalos 1 , Davide Menafra 1 , Michele Castoro 1 , Chiara Simeoli 1 , Annamaria Colao 1,2 , Rosario Pivonello 1,2 & Renata Simona Auriemma 1
1Università Federico II di Napoli, Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Unità di Andrologia e Medicina della Riproduzione e della Sessualità Maschile e Femminile (FERTISEXCARES), Naples, Italy; 2Federico II University of Naples, Unesco Chair for Health Education and Sustainable Development, Naples, Italy
Polycystic ovary syndrome (PCOS) is characterized by menstrual irregularities and clinical and biochemical hyperandrogenism, and is associated with insulin resistance, visceral obesity and metabolic disorders. The aim of the current study was to compare the effects of inositol isomers (INO) and metformin (MET) on the clinical, metabolic and hormonal aspects of PCOS. In 94 PCOS women, clinical (weight, BMI, waist circumference - WC, menstrual intervals, Ferriman-Gallway score - FGS), metabolic (fasting glucose and insulin, HOMA-IR, HOMA-beta, lipid profile) and hormonal [FSH, LH, estradiol (E2), androstenedione (A), testosterone (T)] parameters were retrospectively investigated before (T0) and after 6 months (T6) of treatment with INO (Group 1, n=36) or MET (Group 2, n=58). INO was administered in the 3 following formulations (F): F1, myo-inositol 1000 mg + D-chiro-inositol 200 mg; F2, myo-inositol 1100 mg + D-chiro-inositol 27.6 mg; F3, myo-inositol 1000 mg + alpha-lipoic acid 800 mg. At T0, FGS and hormonal profile were similar between Group 1 and Group 2, except for HDL (P=0.002) and FSH (P=0.02), which were higher in Group 1, whereas weight (P<0.0001), BMI (P<0.0001), WC (P<0.0001), menstrual intervals (P=0.011), fasting insulin (P=0.001), HOMA-IR (P=0.001), HOMA-beta (P=0.001) and triglycerides (P=0.001) were higher in Group 2. At T6, in Group 1, menstrual intervals (P=0.005), FGS (P<0.0001) and testosterone (P=0.021) were significantly reduced compared to baseline, with a trend to a decrease for weight, BMI, A, HOMA-IR and triglycerides. The effects of INO formulations were similar, except for percent increase in E2, which was significantly higher (P=0.027) in F1, compared to F3. At T6, in Group 2, weight (P<0.0001), BMI (P<0.0001), WC (P<0.0001), menstrual intervals (P<0.0001), FGS (P<0.0001), HOMA-IR (P=0.002), total cholesterol (P=0.001), LDL (P<0.0001), triglycerides (P<0.0001), A (P=0.003) and T (P=0.005) were significantly reduced, whereas HDL (P<0.0001) and HOMA-beta (P<0.0001) were significantly increased, compared to baseline. Noteworthy, percent decrease in weight (P<0.0001), BMI (P<0.0001) WC (P=0.018), HOMA-IR (P<0.0001), total cholesterol (P=0.046), LDL (P=0.015) and triglycerides (P=0.041), and percent increase in HDL (P=0.012), were significantly higher in Group 2, compared to Group 1. In conclusion, INO and MET are effective treatments for menstrual irregularities and clinical and biochemical hyperandrogenism in women with PCOS, with different formulations of INO displaying similar efficacy, and MET displaying an apparent greater efficacy over INO on insulin resistance, lipid metabolism, and visceral obesity.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more